DXCM Quote, Financials, Valuation and Earnings

Axogen has a net margin of 13.62% compared to DexCom's net margin of 0.91%. DexCom's return on equity of 26.6% beat Axogen's return on equity of -10.21%.

DexCom has a consensus price target of $101.79, signalling upside risk potential of 48.64%. On the other hand Axogen has an analysts' consensus of $25.00 which suggests that it could grow by 45.69%. Given that DexCom has higher upside potential than Axogen, analysts believe DexCom is more attractive than Axogen.

DexCom has a beta of 1.285, which suggesting that the stock is 28.527% more volatile than S&P 500. In comparison Axogen has a beta of 1.024, suggesting its more volatile than the S&P 500 by 2.388%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Axogen pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $1.1B, which are larger than Axogen quarterly revenues of $49.4M. DexCom's net income of $151.7M is higher than Axogen's net income of $450K. Notably, DexCom's price-to-earnings ratio is 47.89x while Axogen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 7.01x versus 4.05x for Axogen. Usually stocks with elevated PS ratios are considered overvalued.

Edwards Lifesciences has a net margin of 13.62% compared to DexCom's net margin of 27.83%. DexCom's return on equity of 26.6% beat Edwards Lifesciences's return on equity of 50.81%.

DexCom has a consensus price target of $101.79, signalling upside risk potential of 48.64%. On the other hand Edwards Lifesciences has an analysts' consensus of $80.42 which suggests that it could grow by 18.36%. Given that DexCom has higher upside potential than Edwards Lifesciences, analysts believe DexCom is more attractive than Edwards Lifesciences.

DexCom has a beta of 1.285, which suggesting that the stock is 28.527% more volatile than S&P 500. In comparison Edwards Lifesciences has a beta of 1.123, suggesting its more volatile than the S&P 500 by 12.315%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edwards Lifesciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Edwards Lifesciences pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $1.1B, which are smaller than Edwards Lifesciences quarterly revenues of $1.4B. DexCom's net income of $151.7M is lower than Edwards Lifesciences's net income of $385.6M. Notably, DexCom's price-to-earnings ratio is 47.89x while Edwards Lifesciences's PE ratio is 9.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 7.01x versus 7.11x for Edwards Lifesciences. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 13.62% compared to DexCom's net margin of 16.85%. DexCom's return on equity of 26.6% beat Insulet's return on equity of 43.11%.

DexCom has a consensus price target of $101.79, signalling upside risk potential of 48.64%. On the other hand Insulet has an analysts' consensus of $314.06 which suggests that it could grow by 28.36%. Given that DexCom has higher upside potential than Insulet, analysts believe DexCom is more attractive than Insulet.

DexCom has a beta of 1.285, which suggesting that the stock is 28.527% more volatile than S&P 500. In comparison Insulet has a beta of 1.285, suggesting its more volatile than the S&P 500 by 28.544%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $1.1B, which are larger than Insulet quarterly revenues of $597.5M. DexCom's net income of $151.7M is higher than Insulet's net income of $100.7M. Notably, DexCom's price-to-earnings ratio is 47.89x while Insulet's PE ratio is 42.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 7.01x versus 8.73x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care has a net margin of 13.62% compared to DexCom's net margin of 0.27%. DexCom's return on equity of 26.6% beat Tandem Diabetes Care's return on equity of -37.18%.

DexCom has a consensus price target of $101.79, signalling upside risk potential of 48.64%. On the other hand Tandem Diabetes Care has an analysts' consensus of $41.65 which suggests that it could grow by 129.1%. Given that Tandem Diabetes Care has higher upside potential than DexCom, analysts believe Tandem Diabetes Care is more attractive than DexCom.

DexCom has a beta of 1.285, which suggesting that the stock is 28.527% more volatile than S&P 500. In comparison Tandem Diabetes Care has a beta of 1.446, suggesting its more volatile than the S&P 500 by 44.616%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Tandem Diabetes Care pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $1.1B, which are larger than Tandem Diabetes Care quarterly revenues of $282.6M. DexCom's net income of $151.7M is higher than Tandem Diabetes Care's net income of $755K. Notably, DexCom's price-to-earnings ratio is 47.89x while Tandem Diabetes Care's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 7.01x versus 1.27x for Tandem Diabetes Care. Usually stocks with elevated PS ratios are considered overvalued.